Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CCL17-producing cDC2s are essential in end-stage lupus nephritis and averted by a parasitic infection
Laura Amo, … , Juan Wu, Silvia Bolland
Laura Amo, … , Juan Wu, Silvia Bolland
Published June 1, 2021
Citation Information: J Clin Invest. 2021;131(11):e148000. https://doi.org/10.1172/JCI148000.
View: Text | PDF
Research Article Autoimmunity Nephrology Article has an altmetric score of 6

CCL17-producing cDC2s are essential in end-stage lupus nephritis and averted by a parasitic infection

  • Text
  • PDF
Abstract

Lupus nephritis is a severe organ manifestation in systemic lupus erythematosus leading to kidney failure in a subset of patients. In lupus-prone mice, controlled infection with Plasmodium parasites protects against the progression of autoimmune pathology including lethal glomerulonephritis. Here, we demonstrate that parasite-induced protection was not due to a systemic effect of infection on autoimmunity as previously assumed, but rather to specific alterations in immune cell infiltrates into kidneys and renal draining lymph nodes. Infection of lupus-prone mice with a Plasmodium parasite did not reduce the levels or specificities of autoreactive antibodies, vasculitis, immune complex–induced innate activation, or hypoxia. Instead, infection uniquely reduced kidney-infiltrating CCL17-producing bone marrow–derived type 2 inflammatory dendritic cells (iDC2s). Bone marrow reconstitution experiments revealed that infection with Plasmodium caused alterations in bone marrow cells that hindered the ability of DC2s to infiltrate the kidneys. The essential role for CCL17 in lupus nephritis was confirmed by in vivo depletion with a blocking antibody, which reduced kidney pathology and immune infiltrates, while bypassing the need for parasitic infection. Therefore, infiltration into the kidneys of iDC2s, with the potential to prime local adaptive responses, is an essential regulated event in the transition from manageable glomerulonephritis to lethal tubular injury.

Authors

Laura Amo, Hemanta K. Kole, Bethany Scott, Chen-Feng Qi, Juan Wu, Silvia Bolland

×

Figure 1

Parasite infection induces autoreactivity while reducing kidney pathology.

Options: View larger image (or click on image) Download as PowerPoint
Parasite infection induces autoreactivity while reducing kidney patholog...
(A) Schematic representation of the experimental design and timeframes applicable throughout the study (further details are presented in Supplemental Figure 1, A and B). (B–E) Cumulative survival curve and percentage of FcγRIIb-KO (FcγRIIb[KO]) mice and WT mice with the indicated levels of proteinuria following a double (B and C) or single (D and E) infection with Py. The time point of Py infection is indicated by arrows (n = 5 and n = 10 in the survival analysis). Proteinuria levels were measured by chemical strips and are shown in grayscale. (C) n = 14 (months 1–6), n = 9 (months 7–8), and n = 7 (month 9). (E) n = 7 and n = 15–22 for the WT and FcγRIIb-KO groups, respectively. (F) ANA detection in serum of WT or FcγRIIb-KO mice infected with Py at 2 months of age. Shown are representative images of the immunofluorescence assay (original magnification, ×20) and graphs indicating the percentage of mice with the indicated ANA levels. ANA positivity in different serum dilutions is shown in grayscale. n = 7 in WT and n = 22 for the FcγRIIb-KO groups (months 0–2), and n = 5 for the WT and n = 14 for the FcγRIIb-KO groups (months 3–4). (G) Representative H&E-stained images (scale bars: 1 mm [top] and 500 μm [bottom]) and spleen weights for WT (n = 6) and FcγRIIb-KO (n = 17) mice 5 months after a single infection with Py. (H) Serum cytokine levels (IFN-γ, IL-12p70, MCP-1, IL-10, IL-6, and TNF) measured 1 and 5 months after a single Py infection. Genotype and infection status are indicated in G. n = 4 and n = 10 for the WT and FcγRIIb-KO groups. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, and ****P < 0.0001, by log-rank (Mantel-Cox) test was used for survival comparisons (B and D) and 1- and 2-way ANOVA (G and H). Ctrl, control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 10 X users
17 readers on Mendeley
See more details